clinical trial · NCT07079228
A Study to Compare QLS31905 and Chemotherapy With Placebo and Chemotherapy in Participants With Pancreatic Cancer
Qilu Pharmaceutical Co., Ltd.·phase3·recruiting·n = 602
Pancreatic CancerQLS31905Nab-paclitaxel.GemcitabinePlacebo for QLS31905Nab-paclitaxel.Gemcitabine
brief summary
The goal of this study is to evaluate the efficacy of QLS31905 in combination with chemotherapy (nab-paclitaxel plus gemcitabine \[AG\]) versus placebo in combination with chemotherapy (AG) in the treatment of CLDN18.2-positive advanced pancreatic cancer in adult participants.
started
Sep 8, 2025
primary completion
Dec 1, 2028
completion
Sep 1, 2030
last updated
Sep 23, 2025
official title
A Phase 3, Multi-Center, Double-blind, Randomized Study of QLS31905 Plus Chemotherapy Versus Placebo Plus Chemotherapy as First-Line Treatment in Participants With Claudin (CLDN)18.2-Positive Advanced Pancreatic Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol